Production of Clotting Factors Through Biotechnology
Fractionation of plasma is a way to prepare a number of proteins for clinical use, of great value in treatment and prevention of a number of diseases and disease states. Of special importance are the coagulation factor concentrates used for treatment of hemophilia. In treatment of hemophilia A Factor VIII concentrates are used and for treatment of hemophilia B Factor IX concentrates. Before those concentrates were developed there was essentially no treatment for hemophilia patients and life-expectancy was poor. Average lifespan was around 16 years. With the introduction of the Factor VIII and IX concentrates in the 60ties life has completely changed for hemophilia patients. They now can live an almost normal life.
KeywordsFactor VIII Hemophilia Patient Factor Viii Gene Human Factor VIII Plasma Factor VIII
Unable to display preview. Download preview PDF.
- 9.High KA, White II GC, McMillan CW, Macik BG, Roberts HR. In vivo characteristics of rDNA F VIII: The impact for the future in hemophilia care. In: Smit Sibinga CTh, Das C, Overby LR (eds). Biotechnology in blood transfusion. Martinus Nijhoff Publ: Boston/Dordrecht/Lancaster 1988:223–230.Google Scholar